ワクチンアジュバント市場：製品別（エマルジョン、病原体、サポニン、粒子）、投与経路別（皮下、筋肉内）、疾患タイプ別（感染症、癌）、タイプ別（ヒトワクチン、動物用ワクチン）-2028年までの世界予測

Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Global Forecast to 2028

世界のワクチンアジュバント市場規模は、2023年の8億米ドルから2028年には12億米ドルに達すると予測され、予測期間中の年平均成長率は6.9%である。感染症の流行増加、臨床試験中のワクチン数の増加、予防接種プロ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年9月4日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	231	245	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のワクチンアジュバント市場規模は、2023年の8億米ドルから2028年には12億米ドルに達すると予測され、予測期間中の年平均成長率は6.9%である。感染症の流行増加、臨床試験中のワクチン数の増加、予防接種プログラムへの注目の高まりなどの要因が、市場成長にプラスの影響を与えそうです。
"ワクチンアジュバント市場ではアジュバント乳剤分野が圧倒的シェアを占める"
製品に基づき、世界のワクチンアジュバント市場は、病原体成分、アジュバントエマルジョン、微粒子アジュバント、サポニンベースのアジュバント、その他のアジュバントに区分される。2022年には、アジュバント乳剤セグメントが市場で圧倒的なシェアを占めた。COVID-19およびその他の感染症におけるアジュバント乳剤の広範な使用、および伝染病の有病率の上昇は、市場の成長にプラスの影響を与えると思われる。

"2022年の疾患タイプ別では感染症分野が最大シェアを占める"
疾患タイプに基づき、ワクチンアジュバント市場は感染症、癌、その他の疾患に区分される。2022年には、感染症分野がワクチンアジュバント市場で最大のシェアを占めた。感染症の有病率の増加や、インフルエンザなどの感染症に対する新しいアジュバントワクチンの需要の高まりなど、さまざまな要因により、このセグメントが市場で圧倒的なシェアを占めている。

"アジア太平洋地域はより速いペースで成長する可能性が高い"
ワクチンアジュバント市場は、北米、欧州、アジア太平洋、中南米、中東・アフリカに区分される。アジア太平洋地域は予測期間中に大きなCAGRで成長すると予測されている。ワクチン開発に従事する有力企業が存在するため、中国、インド、日本からのワクチンアジュバント需要が増加しており、アジア太平洋地域の市場成長を支えています。さらに、癌罹患率の上昇、ワクチン開発と予防接種に対する政府の取り組みが、市場成長にプラスの影響を与えると予想される要素の一部である。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側80％、需要側20
- 回答者の役職別（サプライサイド）マネージャー - 45%、CXOおよびディレクター - 30%、エグゼクティブ - 25
- 地域別北米：40％、欧州：25％、アジア太平洋地域：20％、中南米：10％、中東・アフリカ：5
レポート掲載企業一覧
- ダイナバックス・テクノロジーズ（米国）
- クロダ・インターナショナル（英国）
- GSK plc（イギリス）
- セピック（フランス）
- ノババックス（米国）
- SPIファーマ（アソシエイテッド・ブリティッシュ・フーズplcの子会社）（英国）
- アジェナス社（米国）
- フィブロ・アニマルヘルス・コーポレーション（米国）
- オーロリウム（バーテルス）（米）
- メルクKGaA（ドイツ）
- Vaxine Pty Ltd.(オーストラリア）
- ハワイバイオテック社（米国）
- CSLリミテッド（オーストラリア）
- OZバイオサイエンシズ（米国）
- インビボジェン（米国）
- アレルギー・セラピューティクス（英国）
- ユーバイオロジクス（韓国韓国
- パシフィック・ジーンテック・リミテッド（米国）
- リボックスGmbH（ドイツ）
- カプチベイト・ファーマシューティカルズLLC（米国）
- クリエイティブ・ダイアグノスティックス（米国）
- LiteVax BV（オランダ）
- ムクタ・インダストリーズ（インド）
- オンコビル社（米国）
- タイターマックスUSA社（米国）。
調査範囲
この調査レポートは、ワクチンアジュバント市場の詳細な実態を明らかにしています。製品、投与経路、疾患タイプ、用途、タイプ、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィール、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、ワクチンアジュバント市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- ワクチンアジュバント市場の成長に影響を及ぼしている主な促進要因（感染症の流行増加、アジュバントワクチン開発のための市場関係者間の協力・提携の増加、製品パイプラインの成長、予防接種プログラムへの注目の高まり）、阻害要因（アジュバントの副作用と高い毒性）、機会（ワクチンへの資金提供の増加、感染症研究活動の増加、植物由来のワクチンアジュバントの開発）、課題（動物由来のワクチンアジュバントに関する懸念、サメ漁の制限）の分析。
- 製品開発/イノベーション：ワクチンアジュバント市場の新発売製品に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、様々な地域のワクチンアジュバント市場を分析しています。
- 市場の多様化：ワクチンアジュバント市場における新規サービス、未開拓地域、最近の開発、投資に関する詳細な情報。
競合評価：ワクチンアジュバント市場におけるDynavax Technologies（米国）、Croda International plc（英国）、GSK plc（英国）、Seppic（フランス）、Novavax（米国）、SPI pharma（米国）、Agenus Inc.

ページTOPに戻る

1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS & EXCLUSIONS 23
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 YEARS CONSIDERED 24
1.3.3 CURRENCY CONSIDERED 24
1.4 RESEARCH LIMITATIONS 24
1.5 STAKEHOLDERS 25
1.6 SUMMARY OF CHANGES 25
1.7 RECESSION IMPACT 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH APPROACH 27
FIGURE 1 RESEARCH DESIGN 27
2.1.1 PRIMARY RESEARCH 28
FIGURE 2 VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS 28
2.1.2 SECONDARY DATA 29
2.2 MARKET SIZE ESTIMATION 30
FIGURE 3 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 30
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 31
2.2.1 INSIGHTS FROM PRIMARIES 32
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY EXPERTS 32
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, ROUTE OF ADMINISTRATION, DISEASE TYPE, APPLICATION, TYPE, AND REGION) 33
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 33
2.3 GROWTH RATE ASSUMPTIONS 34
FIGURE 7 VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 34
FIGURE 8 VACCINE ADJUVANTS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 35
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 36
FIGURE 9 DATA TRIANGULATION METHODOLOGY 36
2.5 STUDY ASSUMPTIONS 36
2.6 RISK ANALYSIS 37

2.7 RECESSION IMPACT ANALYSIS 37
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 37
3 EXECUTIVE SUMMARY 39
FIGURE 10 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 39
FIGURE 11 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) 40
FIGURE 12 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION) 40
FIGURE 13 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 41
FIGURE 14 VACCINE ADJUVANTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 42
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET 43
4 PREMIUM INSIGHTS 44
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 44
FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 44
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2022) 45
FIGURE 17 ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINE ADJUVANTS MARKET IN 2022 45
4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2023 VS. 2028 46
FIGURE 18 ADJUVANT EMULSIONS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028 46
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 20 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
TABLE 2 VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS 49
5.2.1 DRIVERS 49
5.2.1.1 Rising prevalence of infectious diseases 49
5.2.1.2 Increasing collaborations and partnerships among market players for adjuvanted vaccine development 50
5.2.1.3 Growing product pipeline 50
FIGURE 21 PIPELINE OF VACCINE ADJUVANTS 51
5.2.1.4 Growing focus on immunization programs 51
5.2.2 RESTRAINTS 52
5.2.2.1 Side effects and toxicity of adjuvants 52
5.2.3 OPPORTUNITIES 52
5.2.3.1 Growing funding for vaccines and increasing infectious disease research activities 52
TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2019–2023 (USD MILLION) 53
5.2.3.2 Development of plant-based vaccine adjuvants 53
5.2.4 CHALLENGES 54
5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants and shark fishing 54
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 54
FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS 54
5.4 PRICING ANALYSIS 55
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS 55
TABLE 4 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5) 55
5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE 55
TABLE 5 AVERAGE SELLING PRICE OF ADJUVANT EMULSIONS 55
TABLE 6 AVERAGE SELLING PRICE OF PARTICULATE ADJUVANTS 56
TABLE 7 AVERAGE SELLING PRICE OF SAPONIN-BASED ADJUVANTS 56
5.5 TECHNOLOGY ANALYSIS 56
5.6 VALUE CHAIN ANALYSIS 57
FIGURE 23 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 57
5.7 ECOSYSTEM ANALYSIS 58
FIGURE 24 ECOSYSTEM ANALYSIS 58
TABLE 8 SUPPLY CHAIN ECOSYSTEM 58
5.8 KEY CONFERENCES & EVENTS IN 2023–2024 59
TABLE 9 VACCINE ADJUVANTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 59
5.9 REGULATORY ANALYSIS 60
5.9.1 REGULATORY LANDSCAPE FOR VACCINE ADJUVANTS 60
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.10 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 15 VACCINE ADJUVANTS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 THREAT OF NEW ENTRANTS 65
5.10.2 THREAT OF SUBSTITUTES 65
5.10.3 BARGAINING POWER OF SUPPLIERS 66
5.10.4 BARGAINING POWER OF BUYERS 66
5.10.5 DEGREE OF COMPETITION 66
FIGURE 25 PATENT APPLICATIONS FOR VACCINE ADJUVANTS, AUGUST 2013–AUGUST 2023 67
TABLE 16 VACCINE ADJUVANTS MARKET: INDICATIVE LIST OF PATENTS 68
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 69
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 69
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINE ADJUVANTS 69
5.11.2 BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS 70
FIGURE 27 KEY BUYING CRITERIA FOR END USERS 70
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 71
6.1 INTRODUCTION 72
TABLE 17 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 72
6.2 ADJUVANT EMULSIONS 72
6.2.1 EXTENSIVE USE OF ADJUVANT EMULSIONS IN HUMAN VACCINES TO DRIVE GROWTH 72
TABLE 18 ADJUVANT EMULSIONS MARKET, BY REGION, 2021–2028 (USD MILLION) 73
TABLE 19 NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 20 EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
TABLE 21 ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
6.3 PATHOGEN COMPONENTS 74
6.3.1 INCREASING NUMBER OF PROMINENT PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE GROWTH 74
TABLE 22 PATHOGEN COMPONENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 75
TABLE 23 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 24 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 25 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.4 SAPONIN-BASED ADJUVANTS 77
6.4.1 INCREASING USE OF SAPONIN-BASED ADJUVANTS TO SUPPORT MARKET GROWTH 77
TABLE 26 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 27 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 28 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 29 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.5 PARTICULATE ADJUVANTS 79
6.5.1 GROWING DEMAND FOR MINERAL-BASED ADJUVANTS TO BOOST MARKET 79
TABLE 30 PARTICULATE ADJUVANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 31 NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 32 EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 33 ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
6.6 OTHER ADJUVANTS 82
TABLE 34 OTHER VACCINE ADJUVANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 35 NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 36 EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 37 ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 84
7.1 INTRODUCTION 85
TABLE 38 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 85
7.2 INTRAMUSCULAR 85
7.2.1 BETTER ABSORPTION RATE ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION TO DRIVE MARKET GROWTH 85
TABLE 39 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION 86
TABLE 40 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 41 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 42 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 43 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 88
7.3 SUBCUTANEOUS 88
7.3.1 FREQUENT USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET 88
TABLE 44 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION 88
TABLE 45 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 46 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 47 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 48 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.4 OTHER ROUTES OF ADMINISTRATION 91
TABLE 49 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 50 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 51 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 52 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 92
8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 93
8.1 INTRODUCTION 94
TABLE 53 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 94
8.2 INFECTIOUS DISEASES 94
8.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 94
TABLE 54 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 55 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 56 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 57 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 97
8.3 CANCER 97
8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 97
TABLE 58 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 59 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 60 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 61 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 99
8.4 OTHER DISEASES 100
TABLE 62 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 63 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 64 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 65 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 101
9 VACCINE ADJUVANTS MARKET, BY APPLICATION 102
9.1 INTRODUCTION 103
TABLE 66 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
9.2 RESEARCH APPLICATIONS 103
9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 103
TABLE 67 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 68 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 69 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 70 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 106
9.3 COMMERCIAL APPLICATIONS 106
9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 106
TABLE 71 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 72 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 73 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 74 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 108
10 VACCINE ADJUVANTS MARKET, BY TYPE 109
10.1 INTRODUCTION 110
TABLE 75 VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
10.2 HUMAN VACCINE ADJUVANTS 110
10.2.1 INCREASING PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS TO AID MARKET GROWTH 110
TABLE 76 HUMAN VACCINE ADJUVANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 77 NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 78 EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 79 ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
10.3 VETERINARY VACCINE ADJUVANTS 113
10.3.1 INCREASING USE OF ADJUVANTED VACCINES AS PREVENTIVE CARE IN ANIMAL HEALTH TO DRIVE MARKET 113
TABLE 80 VETERINARY VACCINE ADJUVANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 81 NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 82 EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 83 ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115

11 VACCINE ADJUVANTS MARKET, BY REGION 116
11.1 INTRODUCTION 117
TABLE 84 VACCINE ADJUVANTS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
11.2 NORTH AMERICA 117
FIGURE 28 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT 118
TABLE 85 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 86 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119
TABLE 87 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 120
TABLE 88 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 120
TABLE 89 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 121
TABLE 90 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
11.2.1 US 122
11.2.1.1 US to dominate North American market during forecast period 122
TABLE 91 US: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 92 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 123
TABLE 93 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 124
TABLE 94 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 95 US: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
11.2.2 CANADA 125
11.2.2.1 Increasing government funding for vaccine research to drive market growth in Canada 125
TABLE 96 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 97 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 126
TABLE 98 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 126
TABLE 99 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 100 CANADA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
11.2.3 NORTH AMERICA: RECESSION IMPACT 127
11.3 EUROPE 128
TABLE 101 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 102 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 128
TABLE 103 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 129
TABLE 104 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 129
TABLE 105 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 106 EUROPE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
11.3.1 GERMANY 130
11.3.1.1 Increasing investments by various key players to drive market 130
TABLE 107 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
TABLE 108 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 131
TABLE 109 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 132
TABLE 110 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 132
TABLE 111 GERMANY: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
11.3.2 UK 133
11.3.2.1 Rising investments in vaccine development to boost market growth 133
TABLE 112 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133
TABLE 113 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 134
TABLE 114 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 134
TABLE 115 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 134
TABLE 116 UK: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
11.3.3 FRANCE 135
11.3.3.1 Growing focus on new vaccine development to drive market growth 135
TABLE 117 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 136
TABLE 118 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 136
TABLE 119 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 137
TABLE 120 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 121 FRANCE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
11.3.4 ITALY 138
11.3.4.1 Growth in life science research to boost market 138
TABLE 122 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 138
TABLE 123 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 138
TABLE 124 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 139
TABLE 125 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 139
TABLE 126 ITALY: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
11.3.5 SPAIN 140
11.3.5.1 Increasing investments in vaccine development by government and private organizations to support market 140
TABLE 127 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 140
TABLE 128 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 141
TABLE 129 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 141
TABLE 130 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 131 SPAIN: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
11.3.6 REST OF EUROPE 142
TABLE 132 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143
TABLE 133 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 143
TABLE 134 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 144
TABLE 135 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 136 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
11.3.7 EUROPE: RECESSION IMPACT 145
11.4 ASIA PACIFIC 145
FIGURE 29 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT 146
TABLE 137 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 138 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 139 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 148
TABLE 140 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 148
TABLE 141 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148
TABLE 142 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
11.4.1 CHINA 149
11.4.1.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 149
TABLE 143 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150
TABLE 144 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 150
TABLE 145 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 151
TABLE 146 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 147 CHINA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
11.4.2 JAPAN 152
11.4.2.1 Government initiatives to boost market 152
TABLE 148 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 152
TABLE 149 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 152
TABLE 150 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 153
TABLE 151 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 152 JAPAN: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
11.4.3 INDIA 154
11.4.3.1 Growth of biotechnology sector to support market 154
TABLE 153 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154
TABLE 154 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 154
TABLE 155 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 155
TABLE 156 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 157 INDIA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
11.4.4 REST OF ASIA PACIFIC 156
TABLE 158 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
TABLE 159 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 157
TABLE 160 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 157
TABLE 161 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 162 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 158
11.4.5 ASIA PACIFIC: RECESSION IMPACT 158
11.5 LATIN AMERICA 158
11.5.1 GROWING PHARMACEUTICAL & BIOTECHNOLOGY RESEARCH TO DRIVE MARKET GROWTH 158
11.5.2 LATIN AMERICA: RECESSION IMPACT 159
TABLE 163 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 164 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 160
TABLE 165 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 160
TABLE 166 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160
TABLE 167 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
11.6 MIDDLE EAST & AFRICA 161
11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH 161
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 161
TABLE 168 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 162
TABLE 169 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 162
TABLE 170 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 163
TABLE 171 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 163
TABLE 172 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 163
12 COMPETITIVE LANDSCAPE 164
12.1 INTRODUCTION 164
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 164
FIGURE 30 VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 164
12.3 REVENUE SHARE ANALYSIS 165
FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 165
12.4 MARKET SHARE ANALYSIS 165
FIGURE 32 VACCINE ADJUVANTS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 166
TABLE 173 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION 166
12.5 COMPANY EVALUATION MATRIX 167
12.5.1 STARS 167
12.5.2 EMERGING LEADERS 167
12.5.3 PERVASIVE PLAYERS 167
12.5.4 PARTICIPANTS 168
FIGURE 33 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 168
12.5.5 COMPANY FOOTPRINT 169
12.5.5.1 Product footprint of top 25 companies 169
TABLE 174 VACCINE ADJUVANTS MARKET: COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 169
12.5.6 REGIONAL FOOTPRINT OF TOP 25 COMPANIES 170
TABLE 175 VACCINE ADJUVANTS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 170
12.6 START-UP/SME EVALUATION MATRIX 171
12.6.1 PROGRESSIVE COMPANIES 171
12.6.2 STARTING BLOCKS 171
12.6.3 RESPONSIVE COMPANIES 171
12.6.4 DYNAMIC COMPANIES 171
FIGURE 34 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 172
12.7 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 173
TABLE 176 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 173
TABLE 177 VACCINE ADJUVANTS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 173
12.8 COMPETITIVE SCENARIO AND TRENDS 174
12.8.1 PRODUCT LAUNCHES & APPROVALS 174
TABLE 178 VACCINE ADJUVANTS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JULY 2023 174
12.8.2 DEALS 175
TABLE 179 VACCINE ADJUVANTS MARKET: DEALS, JANUARY 2021–JULY 2023 175
12.8.3 OTHER DEVELOPMENTS 176
TABLE 180 VACCINE ADJUVANTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2023 176
13 COMPANY PROFILES 177
(Business overview, Products offered, Recent developments & MnM View)*
13.1 KEY MARKET PLAYERS 177
13.1.1 DYNAVAX TECHNOLOGIES 177
TABLE 181 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW 177
FIGURE 35 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2022) 178
13.1.2 CRODA INTERNATIONAL PLC 182
TABLE 182 CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW 182
FIGURE 36 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2022) 183
13.1.3 GSK PLC 186
TABLE 183 GSK PLC: BUSINESS OVERVIEW 186
FIGURE 37 GSK PLC: COMPANY SNAPSHOT (2022) 187
13.1.4 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP) 190
TABLE 184 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): BUSINESS OVERVIEW 190
FIGURE 38 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY SNAPSHOT (2022) 191
13.1.5 NOVAVAX 193

TABLE 185 NOVAVAX: BUSINESS OVERVIEW 193
FIGURE 39 NOVAVAX: COMPANY SNAPSHOT (2022) 193
13.1.6 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 195
TABLE 186 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): BUSINESS OVERVIEW 195
FIGURE 40 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): COMPANY SNAPSHOT (2022) 196
13.1.7 AGENUS INC. 197
TABLE 187 AGENUS INC.: BUSINESS OVERVIEW 197
FIGURE 41 AGENUS INC.: COMPANY SNAPSHOT (2022) 197
13.1.8 PHIBRO ANIMAL HEALTH CORPORATION 199
TABLE 188 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW 199
FIGURE 42 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2022) 200
13.1.9 AURORIUM (FORMERLY VERTELLUS) 201
TABLE 189 AURORIUM (FORMERLY VERTELLUS): BUSINESS OVERVIEW 201
13.1.10 MERCK KGAA 203
TABLE 190 MERCK KGAA: BUSINESS OVERVIEW 203
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2022) 204
13.1.11 VAXINE PTY LTD. 206
TABLE 191 VAXINE PTY LTD.: BUSINESS OVERVIEW 206
13.1.12 HAWAII BIOTECH INC. 207
TABLE 192 HAWAII BIOTECH INC.: BUSINESS OVERVIEW 207
13.1.13 CSL LIMITED 208
TABLE 193 CSL LIMITED: BUSINESS OVERVIEW 208
FIGURE 44 CSL LIMITED: COMPANY SNAPSHOT (2022) 209
13.1.14 OZ BIOSCIENCES 211
TABLE 194 OZ BIOSCIENCES: BUSINESS OVERVIEW 211
13.1.15 INVIVOGEN 212
TABLE 195 INVIVOGEN: BUSINESS OVERVIEW 212
13.1.16 ALLERGY THERAPEUTICS 214
TABLE 196 ALLERGY THERAPEUTICS: BUSINESS OVERVIEW 214
FIGURE 45 ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2022) 215
13.1.17 EUBIOLOGICS CO., LTD. 216
TABLE 197 EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW 216
13.1.18 PACIFIC GENETECH LIMITED 217
TABLE 198 PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW 217
13.1.19 RIBOXX GMBH 218
TABLE 199 RIBOXX GMBH: BUSINESS OVERVIEW 218
13.1.20 CAPTIVATE PHARMACEUTICALS LLC 219
TABLE 200 CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW 219

13.2 OTHER PLAYERS 220
13.2.1 CREATIVE DIAGNOSTICS 220
13.2.2 LITEVAX B.V. 221
13.2.3 MUKTA INDUSTRIES 222
13.2.4 ONCOVIR, INC. 223
13.2.5 TITERMAX USA, INC. 223
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
14 APPENDIX 224
14.1 DISCUSSION GUIDE 224
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
14.3 CUSTOMIZATION OPTIONS 229
14.4 RELATED REPORTS 229
14.5 AUTHOR DETAILS 230

ページTOPに戻る

Table of Contents

Summary

The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.
“The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market”
Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.

“infectious disease segment accounted for the largest share of the disease type segment in 2022.”
Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.

“Asia Pacific region is likely to grow at a faster pace.”
The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80%, and Demand Side - 20%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
• Dynavax Technologies (US)
• Croda International plc (UK)
• GSK plc (UK)
• Seppic (France)
• Novavax (US)
• SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
• Agenus Inc. (US)
• Phibro Animal Health Corporation (US)
• Aurorium (Vertellus) (US)
• Merck KGaA (Germany)
• Vaxine Pty Ltd. (Australia)
• Hawaii Biotech Inc. (US)
• CSL Limited (Australia)
• OZ Biosciences (US)
• InvivoGen (US)
• Allergy Therapeutics (UK)
• EuBiologics Co., Ltd. (South Korea)
• Pacific GeneTech Limited (US)
• Riboxx GmbH (Germany)
• CaPtivate Pharmaceuticals LLC (US)
• Creative Diagnostics (US)
• LiteVax BV (Netherlands)
• Mukta Industries (India)
• Oncovir, Inc. (US)
• TiterMax USA, Inc. (US).
Research Coverage:
This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Rising prevalence of infectious diseases, increasing collaborations and partnerships among market players for adjuvanted vaccines development, Growing product pipeline, Growing focus on immunization programs), restraints ( Side effects and high toxicity of adjuvants), opportunities (Growing funding for vaccines and increasing infectious disease research activities, development of plant-based vaccine adjuvants) and challenges (Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing) are influencing the growth of vaccine adjuvants market.
• Product Development/Innovation: Detailed insights on newly launched products of the vaccine adjuvants market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the vaccine adjuvants market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccine adjuvants market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France) , Novavax (US), SPI pharma (US), Agenus Inc. (US), Phibro Animal Health Corporation (US) and among others in the vaccine adjuvants market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ワクチンアジュバント市場：製品別（エマルジョン、病原体、サポニン、粒子）、投与経路別（皮下、筋肉内）、疾患タイプ別（感染症、癌）、タイプ別（ヒトワクチン、動物用ワクチン）-2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?